Neoleukin Therapeutics In... (NLTX)
3.49
0.05 (1.45%)
At close: Dec 18, 2023, 9:00 PM
1.45% (1D)
| Bid | n/a |
| Market Cap | 8.2M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -39.36M |
| EPS (ttm) | -12.28 |
| PE Ratio (ttm) | -0.28420195439739415 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 109,095 |
| Avg. Volume (20D) | 5,520 |
| Open | 3.45 |
| Previous Close | 3.44 |
| Day's Range | 3.42 - 3.59 |
| 52-Week Range | 3.42 - 18.80 |
| Beta | 1.10 |
About NLTX
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aqui...
Sector Healthcare
IPO Date Mar 7, 2014
Employees 7
Stock Exchange NASDAQ
Ticker Symbol NLTX
Website https://www.neoleukin.com